Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Diluted Average) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $64.5 million as the latest value for Q3 2024.

  • Quarterly Shares Outstanding (Diluted Average) changed 0.21% to $64.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $64.5 million through Sep 2024, changed 0.21% year-over-year, with the annual reading at $63.3 million for FY2023, 20.58% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2024 was $64.5 million at Crescent Biopharma, roughly flat from $64.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $64.5 million in Q1 2024, with the low at $45.7 million in Q4 2020.
  • Average Shares Outstanding (Diluted Average) over 5 years is $56.9 million, with a median of $52.5 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 23.17% in 2023, then grew 0.1% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $45.7 million in 2020, then increased by 12.54% to $51.5 million in 2021, then grew by 2.1% to $52.5 million in 2022, then increased by 20.58% to $63.3 million in 2023, then rose by 1.8% to $64.5 million in 2024.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $64.5 million, $64.5 million, and $64.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.